famotidine has been researched along with Kidney Failure, Chronic in 16 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It was concluded that the pharmacokinetics of famotidine are significantly altered in children with chronic renal insufficiency; accordingly, dosing should be based on glomerular filtration rate (i." | 2.71 | Famotidine disposition in children and adolescents with chronic renal insufficiency. ( Blumer, JL; Hak, EB; James, LP; Jones, DP; Kearns, GL; Maples, HD; Stowe, CD; Vogt, B; Wells, TG; Wilson, JT, 2003) |
| " Therefore, the same dosage schedule as in uraemia may be applied in patients with dialysis." | 2.37 | Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure. ( Brockmeier, D; Lameire, N; Rosenkranz, B, 1988) |
| "Famotidine dosage adjustment is required in patients with chronic kidney disease." | 1.33 | Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes. ( Hudson, JQ; Nolan, SF; Pentapaty, N; Redmond, AM; Self, T; Weibel, J, 2005) |
| "Midazolam was administered for premedication (5 mg per os) and for the induction of anaesthesia (2 mg intravenous)." | 1.30 | [Prolonged effect of midazolam with delayed postanesthetic recovery from the possible interference of famotidine]. ( Barrau, P; Bazin, JE; Bérard, JP; Giannelloni, C; Gindre, G, 1998) |
| " The authors' five cases and the other seven previously reported emphasize the need for dosage adjustment of famotidine in elderly patients and in those with renal failure, and that these patients should be carefully monitored for development of central nervous system reactions, which sometimes could be very serious." | 1.30 | Central nervous system reactions associated with famotidine: report of five cases. ( Odeh, M; Oliven, A, 1998) |
| " Since famotidine is essentially free of dose-related adverse effects, dose adjustment in patients with mild renal insufficiency and in elderly people is not required; however, either a prolonged dosing interval or a decrease in daily dose during long-term therapy may be adapted for the patients with severe renal insufficiency to avoid accumulation and the potential undesirable effects." | 1.27 | Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. ( Antonello, J; Chremos, AN; Hessey, GA; Lin, JH; Yeh, KC, 1988) |
| " A 7 to 10 fold prolongation of famotidine's elimination half-life (27." | 1.27 | Pharmacokinetics and dynamics of famotidine in patients with renal failure. ( Gladziwa, U; Glöckner, WM; Klotz, U; Krishna, DR; Mann, H; Schmitt, H, 1988) |
| " The bioavailability after oral administration was 49." | 1.27 | Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ( Ando, K; Hachisu, T; Hattori, Y; Oda, Y; Yokoyama, T; Yoshida, T, 1988) |
| " These data indicate that dosage adjustment may be necessary in patients who have renal insufficiency." | 1.27 | Disposition of famotidine in renal insufficiency. ( Abraham, PA; Chremos, AN; Halstenson, CE; Keane, WF; Matzke, GR; Opsahl, JA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mak, SK | 1 |
| Loo, CK | 1 |
| Wong, AM | 1 |
| Wong, PN | 1 |
| Lo, KY | 1 |
| Tong, GM | 1 |
| Lam, EK | 1 |
| Wong, AK | 1 |
| Maples, HD | 1 |
| James, LP | 1 |
| Stowe, CD | 1 |
| Jones, DP | 1 |
| Hak, EB | 1 |
| Blumer, JL | 1 |
| Vogt, B | 1 |
| Wilson, JT | 1 |
| Kearns, GL | 1 |
| Wells, TG | 1 |
| Redmond, AM | 1 |
| Pentapaty, N | 1 |
| Weibel, J | 1 |
| Nolan, SF | 1 |
| Hudson, JQ | 1 |
| Self, T | 1 |
| Yoshimoto, K | 2 |
| Saima, S | 2 |
| Echizen, H | 2 |
| Nakamura, Y | 1 |
| Kondo, T | 1 |
| Yagishita, Y | 1 |
| Ishizaki, T | 2 |
| Oymak, O | 1 |
| Akpolat, T | 1 |
| Arik, N | 1 |
| Yasavul, U | 1 |
| Turgan, C | 1 |
| Caglar, S | 1 |
| Gladziwa, U | 3 |
| Klotz, U | 2 |
| Barrau, P | 1 |
| Giannelloni, C | 1 |
| Gindre, G | 1 |
| Bérard, JP | 1 |
| Bazin, JE | 1 |
| Odeh, M | 1 |
| Oliven, A | 1 |
| Nagasaka, H | 1 |
| Miyazaki, T | 1 |
| Naito, H | 1 |
| Wagner, S | 1 |
| Dakshinamurty, KV | 1 |
| Bechtel, B | 1 |
| Mann, H | 2 |
| Sieberth, HG | 1 |
| Lin, JH | 1 |
| Chremos, AN | 2 |
| Yeh, KC | 1 |
| Antonello, J | 1 |
| Hessey, GA | 1 |
| Krishna, DR | 1 |
| Schmitt, H | 1 |
| Glöckner, WM | 1 |
| Hachisu, T | 1 |
| Yokoyama, T | 1 |
| Oda, Y | 1 |
| Ando, K | 1 |
| Hattori, Y | 1 |
| Yoshida, T | 1 |
| Lameire, N | 1 |
| Rosenkranz, B | 1 |
| Brockmeier, D | 1 |
| Halstenson, CE | 1 |
| Abraham, PA | 1 |
| Opsahl, JA | 1 |
| Keane, WF | 1 |
| Matzke, GR | 1 |
2 reviews available for famotidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure.
Topics: Aged; Aged, 80 and over; Central Nervous System Diseases; Famotidine; Female; Hematoma, Subdural; Hu | 1994 |
Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
Topics: Anti-Ulcer Agents; Cimetidine; Famotidine; Histamine H2 Antagonists; Humans; Kidney Failure, Chronic | 1988 |
1 trial available for famotidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Famotidine disposition in children and adolescents with chronic renal insufficiency.
Topics: Adolescent; Child; Child, Preschool; Famotidine; Histamine H2 Antagonists; Humans; Infant; Kidney Fa | 2003 |
13 other studies available for famotidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
Use of famotidine in adult patients with end-stage renal disease: assessment of dosing and mental status changes.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Famotidine; Female; Histamine H2 Antagonists; Humans; | 2005 |
Reversible neutropenia and thrombocytopenia during famotidine treatment.
Topics: Famotidine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1994 |
Adenylate cyclase of gastric mucosa in patients with chronic renal failure.
Topics: Adenylyl Cyclases; Anti-Ulcer Agents; Cyclic AMP; Famotidine; Female; Gastric Mucosa; Gastrins; Heli | 1996 |
[Prolonged effect of midazolam with delayed postanesthetic recovery from the possible interference of famotidine].
Topics: Accidental Falls; Adjuvants, Anesthesia; Aged; Anesthesia Recovery Period; Anesthesia, General; Drug | 1998 |
Central nervous system reactions associated with famotidine: report of five cases.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Brain Diseases; Famotidine; Female; Histamine H2 Antagon | 1998 |
[Adsorption of other drugs by hemodialysis membrane].
Topics: Adsorption; Amikacin; Ceftizoxime; Cimetidine; Famotidine; Humans; Kidney Failure, Chronic; Membrane | 1991 |
Intragastric long-term pH-metry in hemodialysis patients. A study with famotidine.
Topics: Adult; Drug Administration Schedule; Famotidine; Female; Gastric Acidity Determination; Humans; Hydr | 1991 |
Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Famotidine; Female; Half-Life; Hemofi | 1990 |
Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Anti-Ulcer Agents; Chemical Phenomena; Chemistry; Cr | 1988 |
Pharmacokinetics and dynamics of famotidine in patients with renal failure.
Topics: Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Hemofiltration; Histamine H2 Antagonists; Humans | 1988 |
Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
Topics: Adult; Aged; Anti-Ulcer Agents; Biological Availability; Drug Administration Schedule; Famotidine; F | 1988 |
Disposition of famotidine in renal insufficiency.
Topics: Adult; Aged; Anti-Ulcer Agents; Creatinine; Famotidine; Female; Half-Life; Humans; Kidney Diseases; | 1987 |